Product Description
Ertapenem 153832-46-3
AI Product Description
*The following content is generated by AI and is for reference only.
Ertapenem is a potent, broad-spectrum carbapenem antibiotic designed for the treatment of various bacterial infections. With the chemical formula C19H25N3O6S and CAS Registry Number 178542-07-7, this synthetic compound represents a significant advancement in antimicrobial therapy. Structurally, it features a unique side chain that enhances its stability against certain beta-lactamases while maintaining high affinity for penicillin-binding proteins, thereby effectively inhibiting bacterial cell wall synthesis.
Clinically, Ertapenem is primarily indicated for complicated intra-abdominal infections, pelvic inflammatory diseases, skin and skin structure infections, community-acquired pneumonia, and acute bacterial exacerbations of chronic bronchitis. It is also utilized for uncomplicated urinary tract infections caused by susceptible organisms. A key advantage of Ertapenem lies in its once-daily dosing regimen, which improves patient compliance compared to other carbapenems requiring multiple daily administrations. Furthermore, it exhibits excellent activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, including many strains resistant to other beta-lactam antibiotics. However, it lacks activity against methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Acinetobacter species, necessitating careful selection based on susceptibility patterns.
Administered intravenously or via deep intramuscular injection, Ertapenem achieves therapeutic concentrations rapidly in tissues such as lung parenchyma, abdominal fluids, and soft tissue. Its pharmacokinetic profile supports extended half-life, allowing for convenient outpatient parenteral antibiotic therapy (OPAT). While generally well-tolerated, potential adverse effects may include gastrointestinal disturbances, headache, rash, and rare cases of seizures, particularly in patients with renal impairment or a history of central nervous system disorders. Dose adjustments are crucial for individuals with severe kidney dysfunction to prevent toxicity. As resistance mechanisms evolve, prudent use of Ertapenem remains essential to preserve its efficacy within the broader antimicrobial stewardship framework, ensuring it remains a vital tool in combating serious bacterial infections globally.